Verona Pharma PLC

VRNA

Equity

ISIN null / Valor 36485349

NASDAQ (2025-10-08)

USD 106.91%

Verona Pharma PLC
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Verona Pharma PLC is a pharmaceutical company specializing in the development of respiratory therapies, with a primary focus on treating chronic obstructive pulmonary disease (COPD). The company is advancing a fixed-dose combination formulation of ensifentrine, a novel dual inhibitor, with glycopyrrolate, a long-acting muscarinic antagonist, for maintenance treatment via nebulizers. Verona Pharma is also exploring other delivery methods, such as dry powder inhalers (DPI) and pressurized metered dose inhalers (pMDI), to expand its product lifecycle and collaboration opportunities. While initially targeting the U.S. market, the company has entered a $219 million strategic partnership with Nuance Pharma to develop and commercialize ensifentrine in Greater China, where COPD affects an estimated 100 million people. Beyond COPD, Verona Pharma's pipeline addresses other respiratory conditions with unmet medical needs, including non-cystic fibrosis bronchiectasis (NCFBE), cystic fibrosis, and asthma.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

237%1Y

955%3Y

1,641%5Y

Performance

49.3%1Y

56.9%3Y

60.7%5Y

Volatility